415 CAPITAL

About The Fund

415 CAPITAL is a venture capital firm that specializes in the medical technology sector. With over 25 years of experience, they have strategically funded more than 50 medical technology companies, which includes activities across the CardioVentures and 415 Capital fund families. The firm’s focus lies in seeding and supporting innovative companies at various stages of their development, ranging from pre-seed to Series B. They have successfully enabled 25+ realized exits through trade-sales and IPOs, highlighting their effective investment strategies and commitment to fostering life-saving medical innovations. 415 CAPITAL's investments often target breakthrough technologies and medical advancements with their maximum investment reaching up to $5,000,000 and a minimum of $100,000, finding their 'sweet spot' around $1,500,000. Their portfolio includes a range of companies from those developing AI-powered cardiovascular robotics, commercially ready surgical robotics, to clinical-stage ventures creating bioresorbable vascular scaffolds and technologies for heart failure treatment. Their detailed investment strategy and active involvement in the value creation of their portfolio companies signify their dedication to nurturing and accelerating advancements in medical technology. The firm is comprised of a diverse Investment Team with backgrounds spanning investing, entrepreneurship, biomedical engineering, business development, medicine, and medical device commercialization. Additionally, 415 CAPITAL has a Clinical Team, including physicians and clinical specialists, providing proprietary insights to maintain a critical understanding of clinical practices and medical innovation. Interested parties are encouraged to submit business plans for consideration, as every proposal is carefully reviewed by the firm. Their commitment to Environmental, Social, and Governance (ESG) principles also reflects their dedication to responsible and impactful investing.